News Conference News ACC 2024 Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI Michael O'Riordan April 07, 2024
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2022 Global STEMI Outcomes May Improve With Tracking, GHATI Hints Shelley Wood April 11, 2022
News Conference News ACC 2022 BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short Todd Neale April 11, 2022
News Conference News ACC 2021 Global STEMI Initiative Helps Low- and Middle-Income Countries Achieve Better Metrics L.A. McKeown May 24, 2021
News Conference News ACC 2021 For Young Patients, Sex Gaps in MI Care Start in the Emergency Room Caitlin E. Cox May 06, 2021
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI L.A. McKeown March 09, 2017
News Conference News ACC 2012 ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released Yael L. Maxwell April 02, 2012